>>Signaling Pathways>> GPCR/G protein>> Vasopressin Receptor>>WAY-151932 (VNA-932)

WAY-151932 (VNA-932) (Synonyms: VNA-932; WAY-VNA 932)

Catalog No.GC31475

WAY-151932(VNA-932)는 인간-V2 결합 및 V1a 결합 분석에서 IC50이 80.3nM 및 778nM인 바소프레신 V2 수용체 작용제입니다.

Products are for research use only. Not for human use. We do not sell to patients.

WAY-151932 (VNA-932) Chemical Structure

Cas No.: 220460-92-4

Size 가격 재고 수량
1mg
US$450.00
재고 있음
5mg
US$901.00
재고 있음
10mg
US$1,581.00
재고 있음
20mg
US$2,758.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

WAY-151932 is a vasopressin V2-receptor agonist with IC50 of 80.3 nM and 778 nM in human-V2 binding and V1a binding assay.

WAY-151932 (VNA-932) stimulates cAMP formation in LV2 cells expressing the hV2 receptors in a dose-dependent manner with an EC50 of 0.74±0.07 nM[2].

Oral administration of WAY-151932 (VNA-932) to water-loaded conscious rats produces a dose-dependent decrease in urine volume (ED50=0.14 mg/kg, 2.5% starch in water vehicle) and a corresponding increase in osmolality without altering the urine electrolyte excretion profile[2].

[1]. Molinari AJ, et al. Identification and synthesis of major metabolites of Vasopressin V2-receptor agonist WAY-151932, and antagonist, Lixivaptan. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5796-800. [2]. Failli AA, et al. Pyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists. Bioorg Med Chem Lett. 2006 Feb 15;16(4):954-9.

리뷰

Review for WAY-151932 (VNA-932)

Average Rating: 5 ★★★★★ (Based on Reviews and 4 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for WAY-151932 (VNA-932)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.